Icosavax files for IPO after raising $150M and advancing nanoparticle COVID-19 and RSV vaccines

Seattle-based Icosavax, a 2017 spinout from the University of Washington’s Institute for Protein Design, has filed for an IPO after raising over $150 million and advancing nanoparticle-based COVID-19 and RSV vaccine candidates into early clinical trials with support from a $10 million Gates Foundation grant.

DDavid Baker IIcosavax UUniversity of Washington